Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Research on cells’ ’power centers’ sheds light on AIDS treatments

10.10.2002


Companies that create HIV-AIDS drugs now have key information that could assist in making new medications with fewer side effects.



Researchers Henry Weiner, a professor of biochemistry at Purdue University, Steven Zollo of the National Institute of Standards and Technology and Lauren Wood of the National Cancer Institute, noted the similarity between HIV-AIDS treatment side effects and naturally occurring diseases. Certain HIV-AIDS treatment side effects, such as fat loss and insulin resistance, clinically resemble diseases of the mitochondria, the "power centers" in cells, that affect the functioning of other parts of the cell.

The researchers hypothesized that the drugs to combat HIV infection also might inadvertently affect the functioning of the mitochondria.


"Finding that a drug affects a different target than the one it was designed for is not unusual," said Weiner, an expert on protein processing in the mitochondria. The team speculated that current AIDS treatments using drugs that inhibit HIV proteins also could inhibit a key mitochondrial protein.

This speculation fits the observation by doctors that side effects resembling mitochondrial dysfunction originated after new drugs became part of the standard drug "cocktail" used to treat AIDS patients. Highly Active Antiretroviral Therapy, or HAART, has prolonged the lives of many, but also has been associated with side effects such as diabetes, high cholesterol and the development of fatty deposits.

To test the theory that the drugs were inhibiting the mitochondria, the researchers flooded isolated mitochondria with large amounts of the drugs and then measured the levels of processed protein in the mitochondria.

They found that a number of HIV-AIDS drugs can inhibit mitochondrial processing.

Although these findings suggest a possible link between HIV-AIDS drugs and mitochondrial dysfunction, Weiner said he believes that investigating the mitochondria of patients in treatment, or using tissue culture grown in the lab, is the next step.

"That is the only way to determine whether actual patients taking the medication are more than just slightly compromised by the effects of the HIV-AIDS medication on their mitochondria."

In the interim, Weiner said drug companies may find this information useful in efforts to make medications with fewer side effects.

"Drug companies making new AIDS protease inhibitors can take the enzyme we used and screen new potential drugs and select ones that can fight the virus but not damage the mitochondria," he said.

Drug manufacturers may not have made the connection to the mitochondria because the drugs’ effects are minor, Weiner said.

"The protease inhibitors were weak inhibitors of the mitochondria’s enzymatic processing system," he said. "If they were better inhibitors, that would have likely led to more serious complications in patients."

Weiner also sees other possible impacts from the research, such as potential anticancer treatments. He said scientists might find a "good way to kill tumors," by inhibiting specific enzymes within the tumors’ own mitochondria.

The research was published in the September issue of the Journal Mitochondrion. Weiner’s portion of the research was funded in part by the National Institutes of Health.

Contact: Beth Forbes, (765) 494-2722; forbes@purdue.edu

Source: Henry Weiner, (765) 494-1650; hweiner@purdue.edu

Ag Communications: (765) 494-2722; Beth Forbes, bforbes@aes.purdue.edu

Purdue News Service: (765) 494-2096; purduenews@purdue.edu

Beth Forbes | EurekAlert!
Further information:
http://www.purdue.edu/
http://www.agriculture.purdue.edu/AgComm/public/agnews/

More articles from Health and Medicine:

nachricht UTMB researchers have discovered a new antiviral mechanism for dengue therapeutics
14.07.2020 | University of Texas Medical Branch at Galveston

nachricht Scientists use nanoparticle-delivered gene therapy to inhibit blinding eye disease in rodents
08.07.2020 | Johns Hopkins Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A new path for electron optics in solid-state systems

A novel mechanism for electron optics in two-dimensional solid-state systems opens up a route to engineering quantum-optical phenomena in a variety of materials

Electrons can interfere in the same manner as water, acoustical or light waves do. When exploited in solid-state materials, such effects promise novel...

Im Focus: Electron cryo-microscopy: Using inexpensive technology to produce high-resolution images

Biochemists at Martin Luther University Halle-Wittenberg (MLU) have used a standard electron cryo-microscope to achieve surprisingly good images that are on par with those taken by far more sophisticated equipment. They have succeeded in determining the structure of ferritin almost at the atomic level. Their results were published in the journal "PLOS ONE".

Electron cryo-microscopy has become increasingly important in recent years, especially in shedding light on protein structures. The developers of the new...

Im Focus: The spin state story: Observation of the quantum spin liquid state in novel material

New insight into the spin behavior in an exotic state of matter puts us closer to next-generation spintronic devices

Aside from the deep understanding of the natural world that quantum physics theory offers, scientists worldwide are working tirelessly to bring forth a...

Im Focus: Excitation of robust materials

Kiel physics team observed extremely fast electronic changes in real time in a special material class

In physics, they are currently the subject of intensive research; in electronics, they could enable completely new functions. So-called topological materials...

Im Focus: Electrons in the fast lane

Solar cells based on perovskite compounds could soon make electricity generation from sunlight even more efficient and cheaper. The laboratory efficiency of these perovskite solar cells already exceeds that of the well-known silicon solar cells. An international team led by Stefan Weber from the Max Planck Institute for Polymer Research (MPI-P) in Mainz has found microscopic structures in perovskite crystals that can guide the charge transport in the solar cell. Clever alignment of these "electron highways" could make perovskite solar cells even more powerful.

Solar cells convert sunlight into electricity. During this process, the electrons of the material inside the cell absorb the energy of the light....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Contact Tracing Apps against COVID-19: German National Academy Leopoldina hosts international virtual panel discussion

07.07.2020 | Event News

International conference QuApps shows status quo of quantum technology

02.07.2020 | Event News

Dresden Nexus Conference 2020: Same Time, Virtual Format, Registration Opened

19.05.2020 | Event News

 
Latest News

When Concrete learns to pre-stress itself

15.07.2020 | Architecture and Construction

New lithium battery charges faster, reduces risk of device explosions

15.07.2020 | Power and Electrical Engineering

A new path for electron optics in solid-state systems

15.07.2020 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>